Neurocrine Biosciences (NBIX) CRO logs RSU vesting and tax share withholding

Rhea-AI Filing Summary

Neurocrine Biosciences’ Chief Regulatory Officer, Ingrid Delaet, reported routine equity compensation activity. On January 31, 2026, 801 restricted stock units vested and were converted into 801 shares of common stock at an exercise price of $0.

To cover tax withholding on this vesting, 475 shares were withheld by the company at $136.06 per share, as noted in the footnotes, and no shares were sold on the market. After these transactions, Delaet directly owned 5,056 shares of Neurocrine Biosciences common stock.

Insider Trade Summary

801 shares exercised/converted

Mixed 3 txns

Insider Delaet Ingrid

Role Chief Regulatory Officer

Type	Security	Shares	Price	Value
Exercise	Restriced Stock Unit	801	$0.00	--
Exercise	Common Stock	801	$0.00	--
Tax Withholding	Common Stock	475	$136.06	$65K

Holdings After Transaction: Restriced Stock Unit — 0 shares (Direct); Common Stock — 5,531 shares (Direct)

Footnotes (1)

1. Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of restricted stock units ("RSUs"). No shares were sold. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. This RSU was granted to the Reporting Person on January 31, 2022. In accordance with the terms of the RSU, the award vested as to 800 shares on January 31, 2023, vested as to 800 shares on January 31, 2024, vested as to 801 shares on January 31, 2025, and vested as to 801 shares on January 31, 2026, subject to the terms and conditions of the award.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Delaet Ingrid

(Last) (First) (Middle)

6027 EDGEWOOD BEND CT.

(Street)

SAN DIEGO CA 92130

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
NEUROCRINE BIOSCIENCES INC [ NBIX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Regulatory Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/31/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/31/2026		M		801	A	$0	5,531	D
Common Stock	01/31/2026		F		475(1)	D	$136.06	5,056	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restriced Stock Unit	(2)	01/31/2026		M			801	(3)	(3)	Common Stock	801	$0	0	D

Explanation of Responses:

1. Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of restricted stock units ("RSUs"). No shares were sold.

2. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

3. This RSU was granted to the Reporting Person on January 31, 2022. In accordance with the terms of the RSU, the award vested as to 800 shares on January 31, 2023, vested as to 800 shares on January 31, 2024, vested as to 801 shares on January 31, 2025, and vested as to 801 shares on January 31, 2026, subject to the terms and conditions of the award.

Remarks:

	/s/ Darin Lippoldt, Attorney-in-Fact	02/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did NBIX Chief Regulatory Officer Ingrid Delaet report?

Ingrid Delaet reported the vesting of 801 restricted stock units into 801 Neurocrine Biosciences common shares. As part of this routine equity event, some shares were withheld to cover taxes, and her direct ownership changed accordingly without any open market sale.

How many Neurocrine Biosciences (NBIX) shares does Ingrid Delaet own after this Form 4?

After the reported transactions, Ingrid Delaet directly owns 5,056 shares of Neurocrine Biosciences common stock. This reflects 801 shares from RSU vesting and 475 shares withheld by the company to satisfy tax obligations related to that vesting.

Were any NBIX shares sold in the open market in this Form 4 filing?

No open market sales occurred in this filing. The 475 Neurocrine Biosciences shares were withheld by the company solely to satisfy tax withholding requirements on vested restricted stock units, as explicitly stated in the footnotes to the Form 4.

What is the significance of the 475 NBIX shares withheld at $136.06?

The 475 shares at $136.06 per share were withheld by Neurocrine Biosciences to cover tax withholding on the RSU vesting. This is a non-market transaction and is described in the Form 4 footnotes as tax withholding, with no actual sale of shares.

What RSU award schedule is disclosed for Ingrid Delaet at Neurocrine Biosciences (NBIX)?

The RSU grant, awarded January 31, 2022, vested in annual tranches: 800 shares on January 31, 2023, 800 shares on January 31, 2024, 801 shares on January 31, 2025, and 801 shares on January 31, 2026, subject to the award’s terms and conditions.

What does each restricted stock unit (RSU) represent in this NBIX Form 4?

Each restricted stock unit represents a contingent right to receive one share of Neurocrine Biosciences common stock. When vesting conditions are met, the RSUs convert into an equivalent number of common shares, as reflected in this Form 4 transaction detail.